Celcuity
- Market cap
- 3.22B
- P/E (TTM)i
- -15.30
- P/Bi
- -252.03
- EPSi
- -3.79
- Div yieldi
- 0.00%
- 52W posi
- 20%
Anonymous reader poll. Unscientific, not investment advice.
About Celcuity
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
- Founded
- 2012
- CEO
- Mr. Brian F. Sullivan
- Employees
- 155
- Headquarters
- Minneapolis, Minnesota, United States of America
- Fiscal year end
- 12-31
- Website
- celcuity.com
Company profile
- Exchange
- US
- Symbol
- CELC
- Market-cap rank
- #2398
- Listing date
- 2017-09-20
- Market cap
- 3.22B
- Float cap
- 1.95B
- Shares out
- 48.93M
- Float shares
- 29.72M
Sectors & themes
Quote time 2026-10-08 07:36:52 · For reference only, not investment advice and not tailored to your situation.